This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Tislelizumab
- DrugBank Accession Number
- DB14922
- Background
Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- Tislelizumab
- External IDs
- BGB-A317
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UProgrammed cell death protein 1 antagonistinhibitorHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- ATC Codes
- L01FF09 — Tislelizumab
- Drug Categories
- Amino Acids, Peptides, and Proteins
- Antibodies
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Antineoplastic and Immunomodulating Agents
- Blood Proteins
- Globulins
- Immune Checkpoint Inhibitors
- Immunoglobulins
- Immunoproteins
- MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
- PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
- Proteins
- Serum Globulins
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 0KVO411B3N
- CAS number
- 1858168-59-8
References
- General References
- Not Available
- External Links
- Wikipedia
- Tislelizumab
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Not Yet Recruiting Treatment Non-Muscle-invasive Bladder Cancer (NMIBC) 1 3 Active Not Recruiting Treatment Esophageal Squamous Cell Carcinoma (ESCC) 2 3 Active Not Recruiting Treatment Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma 1 3 Active Not Recruiting Treatment Hepatocellular Carcinoma 1 3 Active Not Recruiting Treatment Non-Small Cell Lung Cancer (NSCLC) 4 3 Active Not Recruiting Treatment Recurrent or Metastatic Nasopharyngeal Cancer 1 3 Active Not Recruiting Treatment Small Cell Lung Cancer (SCLC) 1 3 Completed Treatment Esophageal Squamous Cell Carcinoma (ESCC) 1 3 Enrolling by Invitation Treatment Advanced Malignant Neoplasm 1 3 Enrolling by Invitation Treatment B-cell Malignancy 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- AntagonistInhibitor
- General Function
- Signal transducer activity
- Specific Function
- Inhibitory cell surface receptor involved in the regulation of T-cell function during immunity and tolerance. Upon ligand binding, inhibits T-cell effector functions in an antigen-specific manner. ...
- Gene Name
- PDCD1
- Uniprot ID
- Q15116
- Uniprot Name
- Programmed cell death protein 1
- Molecular Weight
- 31646.635 Da
Drug created at May 20, 2019 14:35 / Updated at February 21, 2021 18:55